#6/II.D.S.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

TO THE JC INFORMATION DISCLOSURE STATEMENT BY APPLICANT

APPLICANT Robert C. Brunham

FILING DATE August 13, 2002

FILING DATE August 13, 2002

SERIAL NO. 10/088,569

FILING DATE August 13, 2002

U.S. PATENT DOCUMENTS

*INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCL	FILING DATE
	5,589,466	Dec. 31, 1998	Felgner et al	514	44	
	:					

FOREIGN PATENT DOCUMENTS

	DOCUMENT NO.	DATE	COUNTRY	CLAS S	SUBC L.	TRANS	LATION
	0192033	Aug. 27,1986	Europe			YES	NO
	WO 98/02546 A	Jan. 22, 1998	PCT				
OTHER DO	40-46 (1995 2. D. M. Pardol 3, 165-169 (3. W.M. McDo (1996) 4. J. B. Ulmer a viral prote 5. B. Wang et	al, Protective efficant and A. M. Beckerie 1995) nnell and F. K. Aska et al., Heterologous n. Vol. 259, 1745-13 al., Gene inoculatio	cy of intramuscular eg, Exposing the imr iri, Molecular Medici protection against in 749 (1993) n generates immuni	munology ine. DNA v influenza b e respons	of naked D vaccines. \ y injection	ONA vaccii /ol. 334, 4	nes.Vol. 2-45
	6. G. J. M. Cox with plasmic	ciency virus type 1. \ , et al., Bovine Herp DNA. Vol. 67, 5664 Intradermal gene in	esvirus 1: Immune r I-5667(1993) nmunization: the po	esponses	of DNA u		

DEC 1 7 2002

1 8 2002 E	2
7 8 2007 SOF	9. J.J. Donnelly et al., Protection against papillomavirus with a polynucleotide vaccine. Vol. 713, 314-320 (1996)
WY & TRADE	10. D. L. Montgomery et al., Heterologous and homologous protection against influenza A by DNA vaccination: Optimization of DNA vectors. Vol.12, 777-783 (1993)
	11. J.J. Donnelly et al., Preclinical efficacy of a prototype DNA vaccine: Enhanced protection against antigenic drift in influenza virus. Vol. 1, 583-587 (1995).
	12. G. H. Rhodes et al., Characterization of humoral immunity after DNA injection. Vol. 82, 229-236 (1994).
	13. H. L. Davis, M. L. Michel, R. G. Whalen, DNA-based immunization induces continuous secretion of hepatitis B surface antigen and high levels of circulating antibody. Vol.2, 1847 –1851 (1993)
	14. J. B. Ulmer. Protective immunity by intramuscular injection of low doses of influenza virus DNA vaccines. Vol. 12, 154 1-1544 (1994).
	15. Z. Xiang and H. C. J. Ertl. Manipulation of the immune response to a plasmid-encoded viral antigen by coinoculation with plasmids expressing cytokines. Vol. 2, 129-135 (1995)
	16. E. F. Fynan et al, DNA vaccines: Protective immunization by parenteral, mucosal, and gene-gun inoculations.Vol. 90, pages. 11478-11482 (1993)
	17. E. Manickan, et al., Genetic immunization against herpes simplex virus. Vol. 155, 259-265 (1995)
	18. M. Sedegah et al , Protection against malaria by immunization with plasmid DNA encoding circumsporozoite protein. Vol. 91, pp. 9866-9870 (1994)
	19. M.A. Barry, et al., Protection against mycoplasma infection using expression-library immunization. Vol. 377, 632-635 (1995)
	20. D. Xu and F. Y. Liew, Genetic vaccination against leishmaniasis. Vol. 12, 1534-1536 (1994)
	21. D. B. Lowrie, et al., Towards and DNA vaccine against tuberculosis. Vol. 12, 1537-1540 (1994)
	22. J. W. Moulder, et al., Interaction of chlamydiae and host cells in vitro. Vol. 55, 143-190 (1991)
	23. J. Schachter, The intracellular life of chlamydia. Vol. 138, 109-139 (1988)
	24. S. D. Hillis and J. N. Wasserheit, Screening for chlamydia-a key to the prevention of pelvic inflammatory disease. Vol. 334, 1399-1401 (1996)
	25. R. C. Brunham and R. W. Peeling, Chlamydia trachomatis antigens: Role in immunity and pathogenesis. Vol. 3, 218-233 (1994).
	26. R. P. Morrison, D.S. Manning, H. D. Caldwell, Immunology of chlamydial trachomatis infections. 1992, pp. 57-84
	27. J. T. Grayston and S-P. Wang, The potential for vaccine against infection of the genital tract with chlamydia trachomatis. Vol. 5, 73-77 (1978)
	28. J.T. Grayston and SP Wang, New knowledge of chlamydia and the diseases they cause. Vol. 132, 87-105 (1975)
	29. H. R. Taylor, et al. Oral immunization with chalmydia major oute rmembrane protein (MOMP) Vol. 29, 1847-1853 (1988)
	30. B.E. Batteiger, et al., Partial protection against genital reinfection by imunization of guinea pigs with isolated outer-membrane proteins of the chlamydial agent of guinea-pig inclusion conjunctivitis. 139, pp. 2965-2972 (1993)
	31. M. Campos et al., A chlamydial major outer membrane protein extract as a trachoma vaccine candidate. Vol. 36, 1477-1491 (1995)
	32. H. Su, M. Parnell, et al., Protective efficacy of parenterally administered MOMP-derived synthetic oligopeptide vaccine in a murine model of Chlamydia trachomatis genital tract infection: serum neutralizing IgG antibodies fo not protect against chlamydial genital tract infection. Vol. 13, 1023-1032 (1995)
	33. T W. Tan, Protection of sheep against chlamydia psittaci infection with a subcellular

1 - 40,20	
w \	DEC
1 6 2002 2	3
& TRADEMARK	34. M. Tuffrey, et al., Heterotypic protection of mice against chlamydial salpingitis and CENT colonization of the lower genital tract with a human serovar F isolate of Chlamydia trachomatis by prior immunization with recombinant serovar L1 major outer-membrane
	protein. 138, 1707-1715 (1992)
	35. Y X. Zhang, J. G. Fox, Y. Ho., Comparison of the major Outer-Membrane protein (MOMP) gene of mouse pneumonitis (MoPn) and hamster SFPD strains of chlamydia trachomatis with other Chlamydia strains.10(6), pages: 1327-1342 (1993)
	36. R. P. Morrison, et al., Gene knockout mice establish a primary protective role for major histocompatibility complex class II-Restricted responses in chlamydia trachomatis genital tract infection. Vol. 63, 4661-4668 (1995)
	37. H. Su and H. D. Caldwell, CD4 ⁺ T cell play a singnificant role in aadoptive immunity to chlamydia trachomatis infection of the mouse genital tract. Vol. 63, 3302-3308 (1995)
	38. J. U. Igietseme et al., Resolution of murine chlamydial genital infection by the adoptive transfer of Biovar-Specific, TH1 Lymphocyte Clone. 5, 317–324 (1993)
	39. J. U. Igietseme, et al., Susceptibility to reinfection after a primary chlamydia genital infection is associated with a decrease of antigen-specific T cells in the genital tract. Vol. 59, 1346-1351 (1991)
	40. D. M. Williams, et al., Cellular immunity to the mouse pneumonitis agent. Vol. 149, 630-639 (1984)
	41. G. Tipples and G. McClarty, Cloning and expression of the chlamydia trachomatis gene for CTP synthetase. Vol. 270, 7908-7914 (1995).
	42. X. Yang, K. et al., Genetically determined differences in IL-10 and IFN-v response correlate with clearance of chlanydia trachomatid mouse pneumonitis infection. Vol.156, 4338-4344 (1996)
	43. Tang et al., Genetic immunization is a simple method for eliciting an immune response. 1992, Vol. 356, pp. 152-154
	44. Davis et al., Direct gene transfer in skeletal muscle: plasmid DNA-based immunization against the hepatitis B virus surface antigen. 1994, Vol. 12: 1503-1509.
	45. Holzman L.B. et al., Identification, molecualr cloning, and characterization of dula leucine zipper bearing kinase. 1994. Pages. 30808-30817. XP-002120730
	46. Stephens, R.S. et al., Genome sequence of an obligate intracellular pathogen of humnas: Chlamydia trachomatis. Vol. 282 (1998) pages. 759-759 XP-002104802
	47. Green et al, "Liposomal Vaccines", Adv. Exp. Med. Biol. 383:83-92
	48. Baxby et al, "Potential use of nonreplicating vectors as recombinant vaccines", Vaccine, 10(1): 8-9
	49. Anderson et al, "Immune response in mice following immunization with DNA encoding fragment C of tetanus toxin, Inf. Immun. 64(8): 3168-3173
	50. Kaul et al, "Expression of the Chlamydia trachomatis major outer membrane protein- encoding gene in Escherichia coli: role of the 3' end in mRNA stability," Gene 87(1):97-104
	51. Douglas et al, "Mutagenesis of the P2 promoter of the major outer membrane protein gene of Chlamydia trachomatis", J. Bacteriol., 178(19):5573-5578
	52. Dascher et al, "Expression and translocation of the chlamydial major outer membrane protein in Escherichia coli", Microbial Pathogenesis, 15: 455-467
	53. M.A. LIU, M.R. Hilleman, R.Kurth, Overview of DNA Vaccines Ann. N.Y. Acad. Sci. 772 (1995) pages 15-20
VALUED:	
XAMINER:	DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if in conformance and not considered. Include copy of this form with next communication with applicant.

- 2002 En 1600/200